...majority stake. The second, renal cancer candidate CM082 (vorolanib; X-82), was developed by Maryland biotech Tyrogenex Inc....
...South San Francisco, Calif. Jihe Group Co. Ltd., Hangzhou, China Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Tyrogenex Inc....

...and Tyrogenex Inc. (Rockville, Md.) will form a JV -- Equinox Sciences LLC -- to develop Tyrogenex's...
...CM082) outside of China. The partners will equally own Equinox. Betta already owns 7% of Tyrogenex...
...Pharmaceuticals Co. Ltd. (SZSE:300558), Hangzhou, China Tyrogenex Inc. , Rockville, Md. Business: Cancer Chris Lieu vorolanib X-82 Betta Pharmaceuticals Co. Ltd. Tyrogenex Inc. Platelet...

...and Tyrogenex Inc. (Rockville, Md.) will form a JV -- Equinox Sciences LLC -- to develop Tyrogenex's...
...CM082) outside of China. The partners will equally own Equinox. Betta already owns 7% of Tyrogenex...
...colorectal cancer drug Vectibix panitumumab, a mAb against EGFR , in China. Chris Lieu vorolanib X-82 Betta Pharmaceuticals Co. Ltd. Tyrogenex Inc. Platelet...

...anti-VEGF drug as needed. The anti-VEGF drugs include Eylea aflibercept, Lucentis ranibizumab and Avastin bevacizumab. Tyrogenex Inc....
...for the duration of the study and safety Status: Completed Phase II enrollment Milestone: NA Nora Weintraub X-82 Tyrogenex Inc. Platelet...

...of Medicine. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Tyrogenex Inc....

...anti-VEGF therapy. Data were presented at the American Academy of Ophthalmology meeting in Las Vegas. Tyrogenex...
...BioCentury, May 18). X-82 is in the Phase II APEX trial to treat wet AMD. Tyrogenex Inc....

...meeting in Denver. X-82 is in the Phase II APEX trial to treat wet AMD. Tyrogenex Inc....

...plus Eylea aflibercept as needed in 132 patients who have been previously treated with Eylea. Tyrogenex Inc....

...cancer play Xcovery Holding Co. LLC (West Palm Beach, Fla.) and oncology and opthalmology company Tyrogenex Inc....
...Fla.). Snyder, who co-founded both companies, will remain chairman at Xcovery and a director at Tyrogenex...